Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 14th Preview)
-
Kidney disease approval
The FDA cleared Travere Therapeutics’ Filspari (sparsentan) for focal segmental glomerulosclerosis (FSGS), handing the company its long-awaited label expansion after a prolonged regulatory path. The approval makes Filspari the first therapy in the US specifically approved for FSGS and opens a major revenue opportunity for the company’s kidney franchise. FSGS is a cause of nephrotic syndrome and can progress to serious kidney impairment. The new indication extends sparsentan’s commercial footprint and reinforces Travere’s focus on rare and difficult-to-treat glomerular diseases, where few targeted options exist. With the FDA’s decision, Travere now has clearer runway for reimbursement and adoption while managing manufacturing and channel readiness for a broader patient population.
-
Radiopharma partnership
Regeneron and Telix announced a $2.1 billion radiopharmaceutical collaboration that combines Regeneron’s antibody discovery platforms with Telix’s radiopharmaceutical development, manufacturing, and global supply chain capabilities. The partnership is structured on a 50/50 cost-and-profit sharing model for four initial programs targeting multiple solid tumors, with options to expand. Telix will receive a $40 million upfront payment for the initial programs, and the companies outlined a milestone framework that could scale materially depending on development outcomes. The collaboration also includes a diagnostics component, with Telix set to lead commercialization and Regeneron receiving a share of profits. The deal underscores how antibody platforms are increasingly being paired with radioactive payload expertise to accelerate next-generation precision oncology and patient selection.
-
Oncology dealmaking: Lilly acquires ADC platform
Eli Lilly agreed to buy CrossBridge Bio for up to $300 million, aiming to strengthen its antibody-drug conjugate (ADC) capabilities with a next-generation, dual-payload approach. CrossBridge, based in Houston, is advancing CBB-120, a TROP2-directed ADC candidate with no clinical data disclosed yet, and the companies expect an IND-enabling path that could start human trials this year. The acquisition adds to Lilly’s existing ADC footprint, following its 2019 purchase of Loxo Oncology and earlier ADC-focused startup deals. CrossBridge’s claims center on a wider therapeutic index and potential improvements in durability and resistance compared with single-payload ADCs. For investors and competitors, the deal signals continued appetite for ADC platform expansion even as firms compete for differentiated payload formats and tumor targeting strategies.
-
FDA draft guidance for gene-therapy safety with NGS
The FDA released draft guidance outlining how sponsors should use next-generation sequencing (NGS) to assess off-target risks in genome-edited human gene therapy products. The draft document—“Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing”—describes non-clinical study design expectations using NGS and bioinformatics for on- and off-target edit analysis. The agency says the resulting data would be submitted in investigational new drug applications to support entry into human trials, and later in biologics license applications for market approval. The FDA also highlighted sequencing strategies that may be appropriate depending on the size of target-site changes, including the use of short-read sequencing for short DNA stretches under 50 base pairs. FDA Commissioner Marty Makary said the agency is focused on standardizing approaches to help sponsors evaluate safety risks more efficiently while minimizing unintended edits that could disrupt chromosomal integrity.
-
Clinical efficacy: Revolution pancreatic cancer milestone
Revolution Medicines reported that daraxonrasib met key survival endpoints in a Phase 3 trial in metastatic pancreatic ductal adenocarcinoma, with results that nearly doubled outcomes versus standard chemotherapy at an early checkpoint. The company said patients receiving the daily KRAS-family inhibitor lived a median of 13.2 months compared with 6.7 months in the chemotherapy arm, prompting Revolution to end the study early. Revolution also pointed to an FDA “national priority” voucher already awarded for daraxonrasib, which could accelerate review timelines after an official submission. The company said it plans to file for regulatory action following the next steps that usually follow Phase 3 readouts. The update increases competitive pressure in pancreatic cancer, where durable survival gains have remained scarce and RAS-pathway drugs are drawing heightened attention.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.